Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent::results from the QUASAR 2 clinical trial and an Australian community-based series by Domingo, Enric et al.
 
 
University of Birmingham
Mutation burden and other molecular markers of
prognosis in colorectal cancer treated with curative
intent:
Domingo, Enric; Camps, Carme; Kaisaki, Pamela J.; Parsons, Marie J.; Mouradov, Dmitri;
Pentony, Melissa M.; Makino, Seiko; Palmieri, Michelle; Ward, Robyn L.; Hawkins, Nicholas
J.; Gibbs, Peter; Askautrud, Hanne; Oukrif, Dahmane; Wang, Haitao; Wood, Joe; Tomlinson,
Evie; Bark, Yasmine; Kaur, Kulvinder; Johnstone, Elaine C.; Palles, Claire
DOI:
10.1016/S2468-1253(18)30117-1
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Domingo, E, Camps, C, Kaisaki, PJ, Parsons, MJ, Mouradov, D, Pentony, MM, Makino, S, Palmieri, M, Ward,
RL, Hawkins, NJ, Gibbs, P, Askautrud, H, Oukrif, D, Wang, H, Wood, J, Tomlinson, E, Bark, Y, Kaur, K,
Johnstone, EC, Palles, C, Church, DN, Novelli, M, Danielsen, HE, Sherlock, J, Kerr, D, Kerr, R, Sieber, O,
Taylor, JC & Tomlinson, I 2018, 'Mutation burden and other molecular markers of prognosis in colorectal cancer
treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series',
The Lancet Gastroenterology and Hepatology, vol. 3, no. 9, pp. 635-643. https://doi.org/10.1016/S2468-
1253(18)30117-1
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
www.thelancet.com/gastrohep   Vol 3   September 2018 635
Articles
Lancet Gastroenterol Hepatol 
2018; 3: 635–43
Published Online 
July 2, 2018 
http://dx.doi.org/10.1016/ 
S2468-1253(18)30117-1
*These authors contributed 
equally
†These authors contributed 
equally
Oxford Centre for Cancer Gene 
Research (E Domingo PhD, 
S Makino PhD, C Palles PhD, 
D N Church DPhil, 
Prof I Tomlinson PhD) and 
Genomic Medicine Theme, 
National Institute for Health 
Research Oxford Biomedical 
Research Centre (E Domingo, 
C Camps PhD, P J Kaisaki PhD, 
M M Pentony PhD, K Kaur PhD, 
D N Church, J C Taylor PhD, 
Prof I Tomlinson), Wellcome 
Trust Centre for Human 
Genetics, Oxford, UK; 
Department of Oncology, 
University of Oxford, Oxford, 
UK (E Domingo, H Wang BSc, 
E Tomlinson BSc, Y Bark MSc, 
E C Johnstone PhD, R Kerr PhD); 
Systems Biology and 
Personalised Medicine 
Division, Walter and Eliza Hall 
Institute of Medial Research, 
Parkville, VIC, Australia 
(M J Parsons BSc, 
D Mouradov PhD, 
M Palmieri PhD, 
Prof P Gibbs MBBS, 
O Sieber PhD); Department of 
Surgery (M J Parsons, O Sieber) 
and Department of Medical 
Biology (D Mouradov, 
M Palmieri, Prof P Gibbs, 
O Sieber), University of 
Melbourne, Parkville, VIC, 
Australia; Office of the Deputy 
Vice-Chancellor (Research) 
(Prof R L Ward PhD) and Faculty 
of Medicine 
(Prof N J Hawkins FRCPA), 
University of Queensland, 
Mutation burden and other molecular markers of prognosis 
in colorectal cancer treated with curative intent: results from 
the QUASAR 2 clinical trial and an Australian 
community-based series
Enric Domingo*, Carme Camps*, Pamela J Kaisaki*, Marie J Parsons*, Dmitri Mouradov, Melissa M Pentony, Seiko Makino, Michelle Palmieri, 
Robyn L Ward, Nicholas J Hawkins, Peter Gibbs, Hanne Askautrud, Dahmane Oukrif, Haitao Wang, Joe Wood, Evie Tomlinson, Yasmine Bark, 
Kulvinder Kaur, Elaine C Johnstone, Claire Palles, David N Church, Marco Novelli, Havard E Danielsen, Jon Sherlock, David Kerr, Rachel Kerr†, 
Oliver Sieber†, Jenny C Taylor†, Ian Tomlinson†
Summary
Background Molecular indicators of colorectal cancer prognosis have been assessed in several studies, but most 
analyses have been restricted to a handful of markers. We aimed to identify prognostic biomarkers for colorectal 
cancer by sequencing panels of multiple driver genes.
Methods In stage II or III colorectal cancers from the QUASAR 2 open-label randomised phase 3 clinical trial and an 
Australian community-based series, we used targeted next-generation sequencing of 82 and 113 genes, respectively, 
including the main colorectal cancer drivers. We investigated molecular pathways of tumorigenesis, and analysed 
individual driver gene mutations, combinations of mutations, or global measures such as microsatellite instability 
(MSI) and mutation burden (total number of non-synonymous mutations and coding indels) for associations with 
relapse-free survival in univariable and multivariable models, principally Cox proportional hazards models.
Findings In QUASAR 2 (511 tumours), TP53, KRAS, BRAF, and GNAS mutations were independently associated with 
shorter relapse-free survival (p<0·035 in all cases), and total somatic mutation burden with longer survival 
(hazard ratio [HR] 0·81 [95% CI 0·68–0·96]; p=0·014). MSI was not independently associated with survival 
(HR 1·12 [95% CI 0·57–2·19]; p=0·75). We successfully validated these associations in the Australian sample set 
(296 tumours). In a combined analysis of both the QUASAR 2 and the Australian sample sets, mutation burden was 
also associated with longer survival (HR 0·84 [95% CI 0·74–0·94]; p=0·004) after exclusion of MSI-positive and 
POLE mutant tumours. In an extended analysis of 1732 QUASAR 2 and Australian colorectal cancers for which 
KRAS, BRAF, and MSI status were available, KRAS and BRAF mutations were specifically associated with poor 
prognosis in MSI-negative cancers. MSI-positive cancers with KRAS or BRAF mutations had better prognosis than 
MSI-negative cancers that were wild-type for KRAS or BRAF. Mutations in the genes NF1 and NRAS from the MAPK 
pathway co-occurred, and mutations in the DNA damage-response genes TP53 and ATM were mutually exclusive. 
We compared a prognostic model based on the gold standard of clinicopathological variables and MSI with our new 
model incorporating clinicopathological variables, mutation burden, and driver mutations in KRAS, BRAF, and 
TP53. In both QUASAR 2 and the Australian cohort, our new model was significantly better (p=0·00004 and 
p=0·0057, respectively, based on a likelihood ratio test).
Interpretation Multigene panels identified two previously unreported prognostic associations in colorectal cancer 
involving TP53 mutation and total mutation burden, and confirmed associations with KRAS and BRAF. Even a 
modest-sized gene panel can provide important information for use in clinical practice and outperform MSI-based 
prognostic models.
Funding UK Technology Strategy Board, National Institute for Health Research Oxford Biomedical Research Centre, 
Cancer Australia Project, Cancer Council Victoria, Ludwig Institute for Cancer Research, Victorian Government.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
There is increasing recognition that treatment of 
common cancers can be modified according to a patient’s 
expected prognosis or response to therapy. For some new 
molecularly guided therapies, powerful biomarkers of 
response are available, which often comprise mutations 
in the specific protein that is targeted. However, for 
conventional cytotoxic therapies, predictive markers of 
response are rare. In view of the modest survival 
benefits that conventional cytotoxic therapies provide for 
patients with common solid malignancies, biomarkers 
of prognosis still have substantial potential clinical 
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importance. Such markers could guide the use of more 
or less aggressive treatment regimens and enable 
clinicians to balance expected outcomes against early and 
late therapeutic toxicities.
Biomarkers can be based on several different types of 
molecule, and high-profile work has highlighted the 
potential use of mRNA profiling for identification of 
groups of colorectal cancers with varying prognoses.1 
Other biomarkers are based on DNA, which is more 
stable and thus generally easier to analyse than mRNA. 
For colorectal cancers treated with curative intent, the 
biomarker most consistently used in clinical practice 
is microsatellite instability (MSI), which usually results 
from defective DNA mismatch repair.2 For stage II 
colorectal cancers, MSI predicts good recurrence-free 
survival, with hazard ratios (HRs) as low as 0·6.3,4 
This association is less strong for stage III cancers, and, 
in stage IV colorectal cancers, MSI positivity is probably 
associated with poor prognosis.5
The availability of a few large datasets 
(>500 participants) from clinical trials has begun to 
clarify the associations between some somatic mutations 
and prognosis of colorectal cancers. However, most of 
these analyses have been restricted to KRAS mutations, 
BRAF mutations, or MSI (appendix pp 6–7). Overall, for 
colorectal cancers treated with curative intent (generally 
stage II or III), data support an association between 
MSI and good prognosis, and weaker evidence suggests 
that KRAS and BRAF mutations, which are mutually 
exclusive, indicate poor prognosis in MSI-negative 
tumours.6–11 However, MSI-positive colorectal cancers 
tend to be BRAF-mutant and KRAS-wild-type, so 
statistical interactions could exist between these 
prognostic biomarkers. Furthermore, whether combin-
ations of other genetic biomarkers provide useful 
prognostic information is unclear.
Screening has been restricted to only a few genes in 
large genetic biomarker studies for two main reasons: 
suboptimal sample quality or quantity, and the cost of 
mutation screening. Because somatic mutations tend 
to co-occur in molecular pathways of tumorigenesis, 
screening of many potentially prognostic mutations in 
the same dataset would be highly desirable to identify 
the primary determinants of tumour behaviour. 
However, the few studies in which such analyses were 
done did not have standardised recruitment and 
follow-up. The prime example is the exome or genome 
sequencing of over 600 colorectal cancers by the Cancer 
Genome Atlas group.12 This work provided an excellent 
dataset for discovery of driver mutations, but is of little 
use for biomarker discovery owing to the heterogeneity 
of the sample set and associated variability in 
clinical data.
In this exploratory study, we aimed to retain the 
advantages of a large clinical trial dataset while assessing 
several prognostic biomarkers for colorectal cancers. To 
this end, we used an 82-gene panel to identify somatic 
mutations in all the major colorectal cancer driver genes 
in more than 500 tumours from the QUASAR 2 clinical 
trial of stage II and III colorectal cancers. We also assessed 
MSI and the ultramutator phenotype resulting from 
POLE mutations.4 We also tested a larger QUASAR 2 
sample set for KRAS and BRAF mutations and MSI. 
Variables associated with survival in QUASAR 2 were 
replication tested in an independent community-based 
cohort, and subjected to a combined analysis.
Research in context
Evidence before this study
The decision to give adjuvant chemotherapy after resection of 
stage II or III colorectal cancer is based mainly on pathological 
factors such as tumour and nodal stage. Microsatellite 
instability (MSI) is the only molecular marker used routinely in 
this setting. However, patient outcomes remain variable, and 
stratification needs to be improved. We searched PubMed with 
the terms “prognosis”, “colorectal”, “colon”, and “rectal” for 
articles published in English up to Feb 16, 2017. Only two large 
studies (>400 profiled patients) in the adjuvant setting had 
screened more than four molecular markers.
Added value of this study
We used next-generation sequencing to analyse a panel of 
82 genes in colorectal cancer from the QUASAR 2 clinical trial, 
and validated our findings in an Australian community-based 
colorectal cancer cohort. We identified high mutation burden 
as an independent marker of good prognosis, even after 
omitting hypermutant tumours with defects in DNA 
mismatch or polymerase proofreading repair. We hypothesise 
that this finding resulted from high neo-epitope levels 
genome-wide. TP53, KRAS, and BRAF mutations were 
additionally independently associated with poor prognosis, 
although the association with BRAF and KRAS was restricted to 
MSI-negative tumours.
Implications of all the available evidence
Although the 15% of stage II or III colorectal cancers with 
hypermutation caused by DNA repair defects have previously 
been shown to have a good prognosis in the non-metastatic 
setting, we have shown that increased mutation burden among 
non-hypermutated colorectal cancers is also associated with 
favourable outcomes. Our data additionally show that the 
prognostic value of MSI is improved by a model based on 
mutation burden and KRAS, BRAF, and TP53 mutations. Use of 
even a modestly sized gene panel provides superior prognostic 
information to tests based on a handful of genes, and could 
allow for existing and novel therapies to be targeted to 
subgroups of patients with poor prognosis, thereby sparing 
patients with good outcomes unnecessary and toxic treatment.
See Online for appendix
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Methods
Study design and participants
In this exploratory study, we assessed prognostic 
biomarkers for colorectal cancers in a large clinical trial 
dataset from a phase 3 clinical trial (QUASAR 2) 
and an independent community-based validation 
cohort. QUASAR 2 was an open-label, randomised 
phase 3 clinical trial13 comprising 1952 patients with 
high-risk stage II or stage III colorectal cancer, who were 
randomly assigned to capecitabine alone or capecitabine 
plus bevacizumab, without radiotherapy. Median 
follow-up was 4·92 years (IQR 4·00–5·16). Overall or 
disease-free survival did not differ significantly between 
the two groups at 3 years’ follow-up.13 Similar results 
have been recorded in two other trials.14,15 We obtained 
clinico pathological data (appendix p 8) from the 
QUASAR 2 trial database. Some data were converted to 
binary variables—ie, sex, location (proximal vs distal), 
and depth of invasion (T4 vs T1, T2, or T3) and lymph 
node metastasis (N2 or N1 vs N0) according to the TNM 
grading system. Age and grade were assessed as 
continuous variables.
The community-based series included 657 patients 
with stage II or III colorectal cancer who were treated at 
the Royal Melbourne Hospital (Parkville, VIC, 
Australia), Western Hospital Footscray (Footscray, VIC, 
Australia) or St Vincent’s Hospital (Sydney, NSW, 
Australia) between Jan 1, 1993, and Dec 31, 2009 
(appendix p 8). Individuals with hereditary colorectal 
cancer syndromes were excluded. All patients received 
standard neoadjuvant or adjuvant fluorouracil-based 
chemotherapy or concurrent chemoradiotherapy. In 
this patient series, stage II disease was deemed low risk 
when tumours were T3/N0; otherwise it was judged 
high risk. All patients provided written informed 
consent, and the study was approved by medical ethics 
committees at all three sites.
Procedures
Colorectal cancer samples from UK QUASAR 2 were 
collected for molecular analysis. 40 μm scrolls were cut 
from formalin-fixed paraffin-embedded specimens of 
colorectal cancers that had greater than 80% estimated 
purity, and from healthy bowel; 10 μm sections were cut 
from the remaining colorectal cancers and needle 
microdissected to enrich for tumours with a 
haematoxylin and eosin section as a guide. Peripheral 
blood samples were also available from most patients. 
DNA was extracted from formalin-fixed paraffin-
embedded tissue with the DNeasy kit (Qiagen, Hilden, 
Germany) and from blood with the Maxwell 16 Blood 
DNA Purification Kit (Promega, Madison, WI, USA). 
The whole cohort was analysed by Sanger sequencing 
for selected mutations and for MSI (appendix pp 1–3), 
and a subset of tumours was also analysed with an Ion 
Torrent (Life Technologies, Guildorf, CT, USA) 
sequencing gene panel for 82 genes (appendix p 9). We 
eliminated mutations with a high probability of being 
artifacts and cancers with high levels of artifactual 
hypermutation owing to ex-vivo cytosine deamination 
(appendix pp 2–3, 32).
We identified all probable driver mutations (appendix 
p 14) and selected the 13 most commonly mutated genes 
(ie, mutated in eight or more tumours) for further 
analysis to identify mutations tending to occur together 
in genetic pathways (appendix pp 17, 35–36). High-depth 
sequencing allowed us to identify tumours carrying 
somatic mutations at substantially reduced allele 
frequency (suggestive of subclonal status).
From the community-based series, fresh-frozen 
tumours and matched normal specimens were retrieved 
from hospital tissue banks. A subset of these tumours 
was screened in 113 genes by targeted next-generation 
sequencing, the others were screened with conventional 
PCR-based sequencing (appendix pp 4–5); choice  of 
screening method was based on the availability of 
funding. All patients were prospectively followed up per 
the standard Australian National Health and Medical 
Research Council guidelines, with a median follow-up of 
60 months (IQR 36–69).
We investigated the prognostic associations of KRAS 
and BRAF mutations in relation to MSI status by 
pooling data from the QUASAR 2 gene panel, the 
Australian validation set, and additional QUASAR 2 and 
stage II or III Australian colorectal cancers that had 
been analysed for MSI and by Sanger sequencing for 
KRAS or BRAF mutations (appendix p 8) for an 
extended set of patients. Similar analyses were also 
done in the extended cohorts, whereby TP53 status 
derived from either next-generation sequencing or 
Sanger sequencing was added.
Statistical analysis
Individual driver gene mutations, combinations of 
mutations, or global measures such as MSI or mutation 
burden (total number of non-synonymous mutations 
and coding indels) were tested for associations with 
relapse-free survival in univariable and multivariable 
models, principally Cox proportional hazards models in 
accordance with published guidelines (appendix p 10).16 
We used the likelihood ratio test to compare a prognostic 
model based on the gold standard of clinicopathological 
variables and MSI with our new model, and did 
10% leave-out cross-validation analysis to confirm the 
robustness of these results. To test whether the 
prognostic effect of mutation burden was due to 
hypermutation only, the same model was run in the 
subset of tumours without MSI or pathogenic POLE 
mutations. All survival analyses were two-sided and 
were deemed significant if p  values were less than or 
equal to 0·05. Univariable results with p values less than 
0·1 were taken forward to be tested in multivariable 
models. Further details of patients and analytic methods 
are in the appendix (p 5). 
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Because several mutations co-varied, we searched 
for primary associations by multivariable regression, 
hierarchical clustering, and Bayesian networks (appendix 
p 4). All analyses were done in STATA (version 10), 
R  (version 3.4.1), or Banjo (version 2.2.0). Research 
materials supporting this publication can be accessed by 
contacting the corresponding author.
Role of the funding source
The study funders had no role in the study design; data 
collection, analysis, or interpretation; or writing of the 
report. The corresponding author had full access to all 
study data and final responsibility for the decision to 
submit for publication.
Results
598 tumours from the QUASAR 2 clinical trial were 
sequenced for 82 genes. After exclusion of mutations 
with a high probability of being artifacts and cancers with 
high levels of artifactual hypermutation owing to ex-vivo 
cytosine deamination, 511 tumours remained for further 
analysis (appendix pp 2–3).
The 13 most commonly mutated genes (APC, TP53, 
KRAS, PIK3CA, BRAF, FBXW7, SMAD4, ATM, PTEN, 
NF1, CTNNB1, GNAS, and NRAS)—ie, mutated in 
eight or more tumours—were selected for further 
analysis to identify mutations tending to occur together 
in genetic pathways (appendix p 14). In addition to 
known associations, such as those between BRAF 
mutation and MSI or between mutations of KRAS and 
PIK3CA, new unreported ones were found. Multivariable 
regression, hierarchical clustering, and Bayesian 
networks showed that mutations in NF1, a negative 
regulator of the Ras pathway, were positively associated 
with NRAS mutations, but not with mutations in KRAS 
or BRAF (appendix pp  17, 35–36). SMAD4 mutations 
were associated with BRAF mutations but not with 
KRAS or NRAS changes (appendix pp 17, 35–36), 
suggesting possible synergy between BRAF and the 
TGFβ or BMP pathways. Additionally, logistic regression 
and Bayesian network analyses showed a strong 
negative association between driver mutations in 
TP53 and ATM (appendix pp 17, 35–36). Clustering 
and Bayesian network analysis suggested a positive 
association between ATM and PTEN mutations 
(appendix pp 17, 35–36). Regression analysis between 
molecular and clinical variables showed that KRAS 
mutations were associated with female sex (similar to 
BRAF mutations;12,17 appendix pp 17, 35–36). Additionally, 
mutations in FBXW7 and CTNNB1 were associated with 
high-grade disease (appendix pp 17, 35–36).
High-depth sequencing identified 58 (11%) tumours 
carrying somatic mutations at substantially reduced allele 
frequency, suggesting subclonal status. Of the 13 most 
commonly mutated genes, PIK3CA (p=0·001), ATM 
(p=0·002), and SMAD4 (p=0·05) had lower driver mutation 
allele frequencies than the other genes, suggesting they 
were more often subclonal (appendix p 18). Mutation 
burden, clonal diversity (presence of any identified 
mutation at low allele frequency), and driver mutations in 
the 13 genes were tested for prediction of bevacizumab 
treatment response, with no significant associations 
identified (data not shown).
In QUASAR 2, overall mutation burden and mutations 
in four specific genes (TP53, KRAS, BRAF, and GNAS) 
showed promising individual associations with relapse-
free survival (predefined p<0·10) and were thus selected 
for multivariable analysis, together with T stage, N stage, 
treatment group (because bevacizumab had previously 
been associated with poor prognosis in our patient 
subgroup, although not the whole trial), and MSI (which 
co-varied with mutation burden and is probably the best 
All cases univariable (n=511) All cases multivariable (n=511) MSI-negative and non-pathogenic POLE 
multivariable (n=443)
HR 95% CI p value HR 95% CI p value HR 95% CI p value
KRAS mutation 1·48 1·07–2·05 0·018 1·99 1·37–2·91 3·44 × 10⁻⁴ 2·25 1·51–3·35 6·07 × 10⁻⁵
BRAF mutation 1·42 0·94–2·13 0·093 2·46 1·51–4·03 3·31 × 10⁻⁴ 2·88 1·70–4·85 7·50 × 10⁻⁵
TP53 mutation 1·53 1·08–2·18 0·018 1·63 1·12–2·38 0·011 1·61 1·09–2·38 0·025
GNAS mutation 2·19 0·89–5·35 0·087 2·76 1·08–7·04 0·034 4·00 1·42–11·3 0·009
Mutation burden (quartiles) 0·87 0·75–1·00 0·055 0·81 0·68–0·96 0·014 0·85 0·73–1·00 0·051
MSI 0·73 0·42–1·28 0·271 1·12 0·57–2·19 0·75 ·· ·· ··
Chemotherapy (bevacizumab plus 
capecitabine vs capecitabine)
1·37 0·98–1·92 0·065 1·43 1·02–2·00 0·039 1·55 1·09–2·22 0·015
T4 vs T1, T2, or T3* 2·11 1·52–2·94 8·59 × 10⁻⁶ 2·10 1·50–2·93 1·36 × 10⁻⁵ 2·29 1·61–3·25 3·66 × 10⁻⁶
N1 or N2 vs N0* 1·80 1·22–2·63 0·003 1·85 1·25–2·73 0·002 2·03 1·33–3·09 0·001
Cox proportional hazards analysis was done. The univariable analyses were adjusted by T stage, N stage, and treatment arm (or two of these if the adjustment variable itself was being assessed). Multivariable analysis 
was based on all variables shown. Mutation burden was derived from total number of non-synonymous mutations and coding indels, which are most likely to be functionally relevant, but similar results were 
obtained when other somatic variants were also included (appendix). POLE proofreading mutation is not shown as a prognostic variable because of the low frequency of those cancers (appendix). MSI=microsatellite 
instability. HR=hazard ratio. *According to TNM tumour classification.
Table 1: Associations between clinicopathological molecular variables and relapse-free survival in the QUASAR 2 cohort
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established prognostic factor for colorectal cancer; 
table 1, appendix p 19). Mutation burden (HR 0·81 
[95% CI 0·68–0·96]; p=0·014), mutations in TP53, 
KRAS, BRAF, and GNAS, T stage, N stage, and use of 
bevacizumab were all independently associated with 
poor prognosis (ie, p≤0·05), but MSI was not (HR 1·12 
[95% CI 0·57–2·19]; p=0·75; table 1). To test whether the 
prognostic effect of mutation burden was due to 
hypermutation only, the same model was run in the 
subset of tumours without MSI or pathogenic POLE 
mutations. Mutation burden was no longer significantly 
associated with outcome (HR 0·85 [95% CI 0·73–1·00]; 
p=0·051), although the HR was similar. The other 
variables retained significance similar to that previously 
shown (table 1).
In the Australian community-based cohort, 379 patients 
received adjuvant fluorouracil treatment, of whom 47 also 
received oxaliplatin (no data for oxaliplatin use were 
available for 38). We replication tested our prognostic 
markers in 296 tumours from the Australian cohort 
(appendix pp 8, 37–38), in which all prognostic markers 
identified in QUASAR 2 (except GNAS mutations) had 
been assessed. A multivariable analysis incorporating the 
same clinical and molecular variables and co-variables 
showed that, in agreement with the QUASAR 2 analysis, 
BRAF mutation, TP53 mutation, and mutation burden 
were associated (p≤0·05) with relapse-free survival, 
whereas MSI was not (table 2). KRAS mutation also 
showed a similar prognostic association in the Australian 
patients to that present in QUASAR 2, but this was 
not statistically significant. When MSI-positive and 
ultramutator tumours were excluded from the Australian 
analysis, KRAS mutation was significantly associated 
with prognosis, but BRAF mutation was not (table 2).
A combined analysis of the QUASAR 2 and Australian 
cohorts (n=807), showed that mutations in KRAS, BRAF, 
and TP53, and lower mutation burden were all 
independently associated with poor prognosis, whereas 
MSI was not (figure 1; table 3; appendix p 20). Exclusion of 
MSI-positive and ultramutator cancers did not affect our 
findings (table 3). No significant heterogeneity was noted 
between cohorts and our model persisted in Australian 
patients treated with chemotherapy (data not shown).
We compared a prognostic model based on the gold 
standard of clinicopathological variables and MSI with 
our new model incorporating clinical variables, mutation 
burden, and driver mutations in KRAS, BRAF, and 
TP53. In both QUASAR 2 and the Australian cohort, our 
All cases univariable (n=296)* All cases multivariable (n=253) MSI negative and non-pathogenic POLE 
multivariable (n=209)
HR 95% CI p value HR 95% CI p value HR 95% CI p value
KRAS mutation 1·31 0·92–1·87 0·136 1·51 0·97–2·38 0·066 1·61 1·02–2·59 0·040
BRAF mutation 0·91 0·52–1·64 0·780 2·18 1·08–4·56 0·029 1·79 0·73–4·24 0·204
TP53 mutation 1·19 0·83–1·71 0·334 1·82 1·12–2·73 0·014 1·81 1·09–2·82 0·020
Mutation burden (quartiles) 0·72 0·62–0·85 8·62 ×   10⁻⁵ 0·78 0·63–0·95 0·014 0·82 0·64–0·93 0·008
MSI 0·39 0·18–0·71 0·003 0·62 0·24–1·44 0·247 ·· ·· ··
Chemotherapy (yes vs no) 1·01 0·71–1·44 0·946 0·60 0·34–0·91 0·019 0·51 0·18–0·90 0·018
Radiotherapy (yes vs no) 1·21 0·50–3·02 0·653 1·33 0·53–3·32 0·546 1·29 0·51–3·20 0·603
T4 vs T1, T2, or T3† 2·19 1·54–3·22 2·01 ×   10⁻⁵ 2·38 1·57–3·75 6·34 ×   10–5 2·67 1·73–4·21 1·62 ×   10⁻⁵
N1 or N2 vs N0† 1·40 0·97–2·08 0·070 1·21 0·71–2·04 0·493 1·19 0·66–2·05 0·597
Cox proportional hazards analysis was done. The univariable analyses were adjusted by T stage, N stage, and treatment group (or two of these if the adjustment variable itself was being assessed). Multivariable 
analysis was based on all variables shown. Mutation burden was derived from total number of non-synonymous mutations and coding indels, which are most likely to be functionally relevant, but similar results 
were obtained when other somatic variants were also included (appendix). POLE proofreading mutation is not shown as a prognostic variable because of the low frequency of those cancers (appendix). BRAF was 
tested only for the common V600E variant. GNAS was not tested. MSI=microsatellite instability. HR=hazard ratio. *Missing data for KRAS (n=9), BRAF (n=11), TP53 (n=10), mutation burden (n=11), MSI (n=1), 
and radiotherapy (n=21). †According to TNM tumour classification.
Table 2: Associations between clinicopathological molecular variables and relapse-free survival in the Australian community-based series
Figure 1: Relapse-free survival in the combined QUASAR 2 and Australian cohorts by mutation burden from 
gene-panel analysis (n=672)
Burden data are shown by quartile (highest burden in quartile 4). Cancers that were positive for microsatellite 
instability or with pathogenic POLE mutations were excluded. Cox proportional hazards model results are shown 
for univariable and multivariable analyses with quartile 1–4 as a continuous variable and other co-variables as per 
table 3. The numbers in each quartile are not equal because of ties in mutation burden. HR=hazard ratio.
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new model was significantly better (p=0·00004 and 
p=0·0057, respectively, based on the likelihood ratio 
test). A 10% leave-out cross-validation analysis showed 
these analyses to be robust (appendix p 5).
We explored the prognostic model separately in 
stage II (n=266) and stage III (n=499) colorectal cancers 
and found that the model was significant (p=7·3 × 10–⁸) 
only in stage III disease (appendix pp 21–22), but 
HRs were similar in both stages. Correspondingly, 
despite inherently reduced power, an analysis by tumour 
location (proximal colon, distal colon, rectum) showed 
similar HRs for all biomarkers across sites, even after 
exclusion of hypermutated tumours (appendix pp 23–25). 
Additionally, formal assessment of interactions between 
individual biomarkers and stage or tumour location 
showed no evidence of significant deviation from a 
log-additive model (data not shown).
On the basis of previous reports,6–11 we investigated the 
prognostic associations of KRAS and BRAF mutations 
in relation to MSI status by pooling data from an 
extended set of the QUASAR 2 and Australian cohorts, 
including an additional 676 colorectal cancers from 
QUASAR 2 and 362 stage II or III colorectal cancers 
from the Australian cohort (n=1732). In multivariable 
analysis, MSI was associated with good prognosis 
(HR 0·45 [95% CI 0·31–0·64]; p=0·00001), and KRAS 
(1·22 [1·01–1·48]; p=0·035] and BRAF (1·53 [1·14–2·04]; 
p=0·004) mutations were both associated with poor 
prognosis (appendix p  26). Because the strong co-
variation of these biomarkers could have confounded or 
obscured prognostic effects, we added multiplicative 
interaction terms between MSI and mutations in KRAS 
and BRAF to the multi variable model. Both of these 
interactions were significant (p=0·003 and p=0·023, 
respectively), suggesting differential prognostic effects.
Accordingly, we explored different combinations of 
MSI, KRAS mutation, and BRAF mutation. Compared 
with triple-negative (ie, MSI-negative, KRAS and BRAF 
wild-type) cancers, MSI-negative tumours with KRAS 
(HR 1·35 [95% CI 1·11–1·64]; p=0·003) or BRAF 
(2·02 [1·47–2·76]; 1·20 × 10–⁵) mutations were associated 
with worse prognosis (table 4, figure 2). By contrast, 
MSI-positive colorectal cancers with KRAS (HR 0·28 
[95% CI 0·09–0·89]; p=0·028) or BRAF (0·55 [0·35–0·90]; 
p=0·017) mutations were associated with a significantly 
better prognosis than the triple negatives (table 4), 
although the difference was not significant compared 
with MSI-positive colorectal cancers without KRAS or 
BRAF mutations. The six main subgroups combining 
MSI, KRAS, and BRAF had consistent effects between 
the QUASAR 2 and Australian cohorts (data not shown).
Although MSI was not an independent prognostic 
marker when mutation burden was also assessed, it was 
prognostic in the absence of information about mutation 
burden (appendix p 26). We therefore explored whether 
new prognostic groups within the larger MSI-negative 
subset could be identified with KRAS, BRAF, and TP53, 
given that TP53 mutation remained an independent 
prognostic marker when MSI-positive and ultramutator 
colorectal cancers were excluded from the main analysis 
All cases univariable (n=807)* All cases multivariable (n=764) MSI-negative and non-pathogenic POLE 
multivariable (n=652)
HR 95% CI p value HR 95% CI p value HR 95% CI p value
KRAS mutation 1·40 1·10–1·78 0·006 1·74 1·31–2·29 1·21 × 10⁻⁴ 1·88 1·40–2·51 2·11 × 10⁻⁵
BRAF mutation 1·23 0·88–1·72 0·231 2·21 1·47–3·29 1·02 × 10⁻⁴ 2·32 1·50–3·58 1·49 × 10⁻⁴
TP53 mutation 1·30 1·01–1·67 0·039 1·65 1·24–2·19 4·67 × 10⁻⁴ 1·68 1·24–2·26 0·001
Mutation burden (quartiles) 0·82 0·74–0·92 5·1 × 10⁻⁴ 0·8 0·70–0·91 0·001 0·84 0·74–0·94 0·004
MSI 0·58 0·38–0·89 0·012 0·8 0·46–1·35 0·399 ·· ·· ··
Cohort plus treatment QUASAR 2 
capecitabine
Reference ·· ·· Reference ·· ·· Reference ·· ··
Cohort plus treatment QUASAR 2 
bevacizumab plus capecitabine
1·45 1·04–2·03 0·029 1·44 1·02–2·01 0·034 1·53 1·07–2·18 0·019
Cohort plus treatment Australia 
no chemotherapy
2·04 1·4–2·98 2·2 × 10⁻⁴ 3·48 2·28–5·30 7·04 × 10⁻⁹ 4·05 2·58–6·34 9·96 × 10⁻¹⁰
Cohort plus treatment Australia 
chemotherapy
2·06 1·45–2·93 5·61 × 10⁻⁶ 1·75 1·18–2·58 0·005 1·88 1·25–2·83 0·002
Radiotherapy (yes vs no) 1·56 0·64–3·78 0·326 1·37 0·54–3·41 0·503 1·3 0·51–3·24 0·579
T4 vs T1, T2, or T3† 1·81 1·42–2·29 1·30 × 10⁻⁶ 2·19 1·68–2·83 3·03 × 10⁻⁹ 2·36 1·80–3·09 4·38 × 10⁻¹⁰
N1 or N2 vs N0† 1·45 1·11–1·89 0·006 1·63 1·21–2·20 0·001 1·68 1·21–2·30 0·002
Cox proportional hazards analysis was done. The univariable analyses were adjusted by T stage, N stage, and treatment group (or two of these if the adjustment variable itself was being assessed). 
Multivariable analysis was based on all variables shown. Mutation burden was derived from total number of non-synonymous mutations and coding indels, which are most likely to be functionally relevant, but 
similar results were obtained when other somatic variants were also included (appendix). POLE proofreading mutation is not shown as a prognostic variable because of the low frequency of those cancers (appendix). 
Mutation burden quartile was derived separately for the QUASAR 2 and Australian cohorts because of the different content of the two panels. The cohort/treatment variables are categorical. MSI=microsatellite 
instability. HR=hazard ratio. *Missing data from Australian cohort for KRAS (n=9), BRAF (n=11), TP53 (n=10), mutation burden (n=11), MSI (n=1), and radiotherapy (n=21). †According to TNM tumour classification.
Table 3: Associations between clinicopathological molecular variables and relapse-free survival in the combined QUASAR 2 and Australian community-based series population
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based on gene panels (table 1). Within the MSI-negative 
colorectal cancer set (n=991), tumours with BRAF and 
TP53 mutations had a particularly poor prognosis 
(HR 3·08 [95% CI 1·88–5·03]; p=7·12 × 10–⁶; figure 3; 
appendix p 27). Neither the interaction between TP53 
and BRAF (HR 2·21 [95% CI 0·97–5·03]; p=0·058), nor 
that between TP53 and KRAS (1·13 [0·71–1·80]; p=0·62) 
were significant.
Discussion
In this study, we used overlapping cancer gene mutation 
panels to analyse a cohort from a high-quality clinical 
trial of colorectal cancers treated with curative intent 
and a validation cohort. In multivariable analysis 
incorporating known clinicopathological prognostic 
factors, we showed that low overall mutation burden and 
mutations in KRAS, BRAF, and TP53 were independently 
associated with decreased relapse-free survival after 
colorectal cancer treated with curative intent. These 
findings were present both in the clinical trial cohort and 
in the Australian validation set of community-based 
patients. The fact that we found no molecular marker for 
bevacizumab response in QUASAR 2 or chemotherapy 
response in the Australian cohorts suggests that the 
markers we identified are prognostic, although formal 
demonstration of this hypothesis is difficult because 
most patients received fluorouracil-based chemotherapy.
Use of prognostic molecular markers in management of 
solid tumours is still not widespread, partly because of a 
lack of validated markers and partly because of differences 
between studies, leading to uncertainty about which 
markers to use and their estimated effect sizes. Although 
molecular indicators of colorectal cancer prognosis have 
been assessed in several large studies, analyses in most 
cases have been restricted to a handful of markers.
The complexity of associations between mutations and 
colorectal cancer prognosis is arguably reflected by the 
generally stronger associations of markers in our 
multivariable than in univariable analyses. Furthermore, 
MSI was generally not prognostic in our analyses, 
because its effects were captured by mutation burden 
(somatic single nucleotide variants and small indels). 
However, mutation burden not only strongly co-varied 
with MSI and POLE, but also provided prognostic 
information in MSI-negative colorectal cancers. 
Although high mutation burden has been associated 
with good colorectal cancer prognosis in the context of 
MSI and POLE proofreading deficiency,4 this relation has 
not previously been shown for colorectal cancers without 
those forms of genomic instability. Similar data for other 
tumour types are few,18–20 although in other cancers with 
generally high mutation burdens but without specific 
forms of genomic instability, such as lung carcinoma and 
melanoma, mutation burden has predicted response to 
immune checkpoint inhibitors.21,22
In our study, undetected hypermutator or ultramutator 
cancers could have contributed to the mutation burden 
association, although the frequencies of MSI and POLE 
mutations that we recorded were typical of other studies,4 
and we identified a monotonic relationship between 
mutation burden quartile and relapse-free survival. 
Another potential cause of the mutation burden 
association was non-excluded deamination artifacts if 
they happened to be associated with an unknown factor 
correlated with good prognosis. However, we made 
strenuous efforts to exclude those artifacts, no plausible 
explanatory causes such as tumour age were detectable 
within QUASAR 2, and the Australian validation cohort 
analyses were done in fresh frozen tissue, which was 
unlikely to have deamination. In our study, the association 
between prognosis and mutation burden was sufficiently 
strong that even a modestly sized gene panel should pick 
it up, suggesting that it was representative of mutation 
burden in the exome.23 The underlying reason for that 
Figure 2: Relapse-free survival by combinations of MSI and mutations in KRAS and BRAF in the combined 
extended QUASAR 2 and Australian cohorts
Cancers with pathogenic POLE mutations were excluded. MSI=microsatellite instability.
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KRAS wild-type, BRAF wild-type, MSI negative Reference ·· ··
KRAS mutated, BRAF wild-type, MSI negative 1·35 1·11–1·64 0·003
KRAS wild-type, BRAF mutated, MSI negative 2·02 1·47–2·76 1·20 × 10⁻⁵
KRAS wild-type, BRAF wild-type, MSI positive 0·90 0·56–1·45 0·670
KRAS mutated, BRAF wild-type, MSI positive 0·28 0·09–0·89 0·028
KRAS wild-type, BRAF mutated, MSI positive 0·55 0·35–0·90 0·017
T4 vs T1, T2, or T3* 2·26 1·88–2·71 3·32 × 10⁻¹⁸
N1 or N2 vs N0* 2·07 1·65–2·59 2·62 × 10⁻¹⁰
The p value for the interaction between MSI and BRAF is 0·003; the p value for the interaction between MSI and KRAS is 
0·023. Results are from multivariable analysis adjusted by cohort groups. Six patients in very rare subgroups are not 
shown. MSI=microsatellite instability. *According to TNM tumour classification.
Table 4: Prognosis associated with subgroups by KRAS mutation, V600E BRAF mutation, and MSI in all 
cohorts (n=1732)
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association is unclear, although anti-tumour immune 
responses are evidently the prime candidate.18–20
We showed a strong negative association between 
driver mutations in TP53 and ATM, two key mediators 
in the DNA damage response, suggesting that these 
mutations are alternative DNA damage response 
inactivators. We also found a positive association between 
ATM and PTEN mutations; PTEN is phosphorylated 
by ATM in response to DNA-damaging agents, thus 
inducing autophagy.24 Mutations in FBXW7 and CTNNB1 
were associated with high-grade disease, the latter 
suggesting that activation of the Wnt pathway through 
CTNNB1 rather than APC mutation might predispose to 
poorly differentiated colorectal cancers.
The interplay between KRAS, BRAF, and TP53 
mutations, MSI, and mutation burden in our data set is 
intriguing. These mutations co-vary strongly (appendix), 
and are additionally associated with other molecular 
variables. Thus, to decipher primary associations is 
extremely challenging. Nevertheless, our study strongly 
supports the reported poor prognosis of MSI-negative 
colorectal cancers with KRAS or BRAF mutations6–11 
compared with MSI-negative colorectal cancers wild-type 
for these genes and unselected MSI-positive colorectal 
cancers. Additionally, we showed that KRAS or BRAF 
mutation could be associated with improved prognosis 
in MSI-positive colorectal cancers. TP53 has not 
previously been consistently reported as a prognostic 
marker for colorectal cancer in the curative setting, but 
very few large studies have included a sufficiently 
comprehensive molecular analysis of KRAS, BRAF, 
TP53, and MSI. Notably, addition of these four prognostic 
markers improved outcome prediction compared with 
current clinical guidelines based on MSI.
The strengths of our study are that several potential 
biomarkers were screened in a large, high-quality clinical 
trial and a community-based cohort. We have carefully 
done quality-control analysis to derive high-quality 
mutation calls. For mutation burden, the study is arguably 
limited by the size of the gene panels used, and a larger 
panel or exome and genome sequencing might detect even 
stronger associations with prognosis. Limitations include 
the low numbers of patients with stage II disease in the 
sample set, which means that the utility of our model in 
such patients remains formally unproven. Although we 
found our model to be significant only in stage III disease 
(appendix p 22), HRs were similar in both stages, 
suggesting that the lack of significance for stage II disease 
was the result of lower power in that set. Furthermore, we 
cannot formally distinguish between the model being 
prognostic or predictive for fluorouracil response. Another 
potential weakness is the different treatment regimens 
used in each cohort, although regimen was incorporated 
as a co-variable in the analyses. Finally, our study might 
have suboptimal power to draw firm conclusions about 
outcomes in small patient groups or subgroups, such as 
those with combinations of several molecular variables.
Advances in molecular testing hold considerable 
promise for the delivery of precision cancer medicine, 
but their clinical use to date has largely been limited to 
analysis of small numbers of actionable variants. 
In colorectal cancer, these include KRAS and NRAS 
mutation testing for prediction of resistance to 
anti-EGFR therapies,25 and MSI, which identifies 
stage II tumours with excellent prognosis26 and stage IV 
tumours likely to respond to immune checkpoint 
inhibition. Our findings show that the use of even a 
modest-sized gene panel can provide clinically useful 
Figure 3: Relapse-free survival by combinations of mutations in KRAS, BRAF, and TP53 in MSI-negative tumours in the combined extended QUASAR 2 and 
Australian cohorts
Cancers that were MSI positive or with pathogenic POLE mutations were excluded. MSI=microsatellite instability.
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information beyond individual driver mutations. 
Tumour mutation burden displaced MSI and POLE as a 
marker of prognosis in multivariable analysis, thus 
extending the group of colorectal cancers with good 
prognoses to include those with high mutation burden 
in the absence of a specific underlying mutator 
phenotype. Although we were unable to test whether 
mutational load is predictive for immunotherapy 
response, this correlation is well documented in other 
tumour types, including melanoma and lung and 
ovarian cancers.27 Accordingly, our results suggest that 
the use of tumour mutation burden as a prognostic and 
predictive marker in colorectal cancer is worthy of 
further exploration, beyond tumours with MSI or POLE 
mutation. Other genome-wide molecular phenotypes, 
such as mutational signatures,28 are also likely to have a 
role in cancer management in the future.
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